Key Highlights
- Third quarter Revenue was USD 202.7 million against an estimate of USD 191.33 million and USD 205.7 million last year.
- Adjusted loss per share was USD 0.11 against an estimated USD 0.20 loss; GAAP loss per share was USD 0.46.
- On October 19, 2026 the company agreed to sell its Prenatal Health Business for USD 210 million in cash.
- Full year 2026 revenue guidance of USD 780 million to USD 790 million had its mid-point raised.
Myriad Genetics, Inc. (NASDAQ:MYGN) used its third quarter report to describe a narrower strategic focus. On October 19, 2026, it entered a definitive agreement to sell its Prenatal Health business to Labcorp for USD 210 million in cash, plus the value of related inventory at closing. Quarterly revenue of USD 202.7 million compares with an estimate of USD 191.33 million, and the adjusted loss per share of USD 0.11 compares with an estimated loss of USD 0.20.
Strategy Centers on the Cancer Care Continuum
President and chief executive Sam Raha said the Prenatal Health sale supports the intent to increase profitable growth by focusing on the Cancer Care Continuum, which covers screening, treatment selection, monitoring and remission surveillance. He also said third quarter results came in ahead of management's own plan and tied them to payer engagement and revenue cycle management work. The sale is subject to customary closing conditions, including regulatory approvals, and the company stated a closing target of early 2027.
The company also continues to engage the Molecular Diagnostics Program, administered by Palmetto GBA, on a Local Coverage Determination for Medicare coverage of its Precise MRD test in breast cancer.
Revenue, Volume and Margins
Revenue of USD 202.7 million compares with USD 205.7 million in the third quarter of 2025, a stated 1% decrease year over year and a 6% sequential increase. Total average revenue per test rose 7% sequentially and 1% year over year, while total test volume declined 1% and 2%, respectively.
Cancer Care Continuum revenue was USD 123.9 million against USD 122.5 million, and Mental Health revenue, which is the GeneSight test, was USD 39.5 million against USD 38.7 million. Prenatal Health revenue was USD 39.3 million against USD 44.5 million, with volume of 138,000 tests, down 11%.
Gross Margin was 67.9%, which the company said was down 200 basis points from the prior-year quarter, reflecting lower test volumes and added laboratory personnel. Operating expenses were USD 177.6 million against USD 167.1 million, and the operating loss was USD 39.9 million against USD 23.3 million. Net loss was USD 43.9 million, or USD 0.46 per share, against USD 27.4 million, or USD 0.29 per share. Adjusted EBITDA was negative USD 5.3 million against positive USD 10.3 million.
Cash Flow and Guidance
Cash used in operations was USD 6.5 million, while adjusted operating Cash Flow was USD 3.7 million. Adjusted free cash flow was USD 1.6 million. Cash and cash equivalents were USD 107.1 million at September 30, 2026.
For full year 2026, management guided to revenue of USD 780 million to USD 790 million, with Cancer Care Continuum and Mental Health revenue of USD 620 million to USD 630 million and Prenatal Health revenue of about USD 160 million. Adjusted gross margin is guided at 66% to 67%, and the company said margins fluctuate from quarter to quarter with product mix and pricing.
Reference Points for Investors
Revenue of USD 202.7 million sits alongside a gross margin of 67.9%, an operating loss of USD 39.9 million and cash of USD 107.1 million.
Management named the following markers: a Prenatal Health sale price of USD 210 million in cash, a closing target of early 2027, and full year revenue guidance of USD 780 million to USD 790 million. It also pointed to continued payer engagement and revenue cycle initiatives and the pursuit of Medicare coverage for Precise MRD in breast cancer.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...